A Study of Continued Use of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting

Sponsor
Janssen Sciences Ireland UC
Study ID
NCT07746765
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of this study is to find out how long a participant keeps taking guselkumab or continues with their treatment plan without stopping (treatment persistence) in participants with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are inflammatory bowel diseases, a group of inflammatory conditions of the colon and small intestine.

Key Dates

First listed
Aug 5, 2026
Start date
Sep 30, 2026
Status verified
Aug 2026
Primary completion
Aug 3, 2029
Completion
Sep 30, 2029

Study Design

Enrollment
35 participants (estimated)

Arms

  • Arm: Moderate-to-Severe Ulcerative Colitis (UC) or Crohn's Disease (CD)
    Participants with confirmed diagnosis of moderate to severe crohn's disease (CD) or ulcerative colitis (UC) treated with guselkumab in accordance with routine clinical practice as per the approved prescribing label will be enrolled. No drug will be provided as a part of this study. Only data available from clinical practice and medical records will be collected within this study.

Primary Outcome Measure

Time to Guselkumab Discontinuation [ Time Frame: Up to Week 96 ]

Central Contacts

Find similar trials

Nationwide
Crohn's disease trialsGastroenterology trialsInflammatory bowel disease trialsAutoimmune disease trials

Related Studies